HK1079543A1 - Process for producing cytotoxic lymphocyte - Google Patents

Process for producing cytotoxic lymphocyte

Info

Publication number: HK1079543A1
Authority: HK; Hong Kong
Prior art keywords: cytotoxic lymphocyte; producing cytotoxic; producing; lymphocyte; fibronectin
Prior art date: 2002-03-25

Application number

HK05111402.4A

Other languages

English (en)

Inventor

Hiroaki Sagawa

Mitsuko Ideno

Ikunoshin Kato

Original Assignee

Takara Bio Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-25

Filing date

2005-12-12

Publication date

2006-04-07

2005-12-12 Application filed by Takara Bio Inc filed Critical Takara Bio Inc

2006-04-07 Publication of HK1079543A1 publication Critical patent/HK1079543A1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Mycology (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Compounds Of Unknown Constitution (AREA)

HK05111402.4A 2002-03-25 2005-12-12 Process for producing cytotoxic lymphocyte HK1079543A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2002084414		2002-03-25
PCT/JP2003/003575 WO2003080817A1 (en)	2002-03-25	2003-03-25	Process for producing cytotoxic lymphocyte

Publications (1)

Publication Number	Publication Date
HK1079543A1 true HK1079543A1 (en)	2006-04-07

Family

ID=28449211

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK05111402.4A HK1079543A1 (en)	2002-03-25	2005-12-12	Process for producing cytotoxic lymphocyte
HK10110610.7A HK1144105A1 (en)	2002-03-25	2010-11-15	Process for producing cytotoxic lymphocyte

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HK10110610.7A HK1144105A1 (en)	2002-03-25	2010-11-15	Process for producing cytotoxic lymphocyte

Country Status (15)

Country	Link
US (3)	US8728811B2 (xx)
EP (3)	EP1496109B1 (xx)
JP (1)	JP4406566B2 (xx)
KR (2)	KR100786054B1 (xx)
CN (3)	CN100591760C (xx)
AT (1)	ATE491021T1 (xx)
AU (2)	AU2003221073B2 (xx)
CA (1)	CA2479288C (xx)
DE (1)	DE60335253D1 (xx)
EA (1)	EA010434B1 (xx)
ES (3)	ES2396447T3 (xx)
HK (2)	HK1079543A1 (xx)
MX (1)	MXPA04009287A (xx)
TW (2)	TW201043699A (xx)
WO (1)	WO2003080817A1 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101633907B (zh)	2001-08-15	2012-09-05	宝生物工程株式会社	抗原特异性细胞毒性t细胞的扩大培养方法
ATE491021T1 (de)	2002-03-25	2010-12-15	Takara Bio Inc	Verfahren zur produktion eines zytotoxischen lymphozyten
CN1839202B (zh) *	2003-08-22	2012-07-18	宝生物工程株式会社	细胞毒性淋巴细胞的制备方法
GB0409775D0 (en) *	2004-04-30	2004-06-09	Mabtech Ab	Assay
KR101279172B1 (ko)	2005-08-17	2013-06-27	다카라 바이오 가부시키가이샤	림프구의 제조 방법
JP4741906B2 (ja) *	2005-08-31	2011-08-10	タカラバイオ株式会社	リンパ球の製造方法
CN101400785B (zh) *	2005-09-30	2013-09-25	宝生物工程株式会社	T细胞群的制备方法
WO2007142300A1 (ja)	2006-06-09	2007-12-13	Takara Bio Inc.	リンパ球の製造方法
US8715718B2 (en) *	2006-07-14	2014-05-06	Rutgers, The State University Of New Jersey	Extracellular matrix production from nanoscale substrate
US20110158954A1 (en) *	2007-03-09	2011-06-30	Mitsuko Ideno	Method for producing gamma delta t cell population
TW200908988A (en) *	2007-05-11	2009-03-01	Takara Bio Inc	Therapeutic agent for cancer
US8470966B2 (en) *	2007-08-10	2013-06-25	Protelica, Inc.	Universal fibronectin type III binding-domain libraries
US20110027242A1 (en) *	2008-03-27	2011-02-03	Takara Bio Inc.	Method for production of transfected cell
EP2471901A4 (en)	2009-08-25	2013-06-26	Takara Bio Inc	PROCESS FOR PRODUCING T-CELL POPULATION IN THE PRESENCE OF RETINOIC ACID
EP2476752A4 (en)	2009-09-11	2013-04-03	Takara Bio Inc	PROCESS FOR THE PRODUCTION OF NATURAL KILLER CELLS
US8809050B2 (en) *	2009-12-08	2014-08-19	Wilson Wolf Manufacturing	Methods of cell culture for adoptive cell therapy
US8956860B2 (en)	2009-12-08	2015-02-17	Juan F. Vera	Methods of cell culture for adoptive cell therapy
KR101988895B1 (ko)	2011-05-19	2019-06-13	도레이 카부시키가이샤	면역 유도제
CN115094036A (zh)	2016-04-08	2022-09-23	爱默蕾大学	使用基于细胞的疗法治疗癌症和传染病的方法
WO2018135646A1 (ja)	2017-01-20	2018-07-26	国立大学法人京都大学	ＣＤ８α＋β＋細胞傷害性Ｔ細胞の製造方法
CN111655842B (zh) *	2018-01-25	2023-10-20	宝生物工程株式会社	淋巴细胞生产方法
CN115516084A (zh)	2020-03-31	2022-12-23	国立大学法人京都大学	T细胞祖细胞的制造方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8516421D0 (en)	1985-06-28	1985-07-31	Biotechnology Interface Ltd	Fibronectins
DE3788796T2 (de)	1986-10-20	1994-05-05	Life Technologies Inc	Serumfreies medium zur proliferation von lymphokin-aktivierten töterzellen.
US5019646A (en)	1987-08-25	1991-05-28	Regents Of The University Of Minnesota	Polypeptides with fibronectin activity
JP2561131B2 (ja) *	1988-06-30	1996-12-04	寳酒造株式会社	細胞接着活性ポリペプチド
GB8909916D0 (en)	1989-04-29	1989-06-14	Delta Biotechnology Ltd	Polypeptides
US5198423A (en) *	1989-05-26	1993-03-30	Takara Shuzo Co., Ltd.	Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
GR1001034B (el)	1989-07-21	1993-03-31	Ortho Pharma Corp	Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
US5188959A (en) *	1989-09-28	1993-02-23	Trustees Of Tufts College	Extracellular matrix protein adherent t cells
JP3104178B2 (ja)	1990-03-30	2000-10-30	寶酒造株式会社	機能性ポリペプチド
JPH04297494A (ja) *	1991-03-26	1992-10-21	Fuji Photo Film Co Ltd	ペプチド誘導体とその用途
JP2729712B2 (ja)	1991-04-23	1998-03-18	寳酒造株式会社	機能性ポリペプチド
JPH07102131B2 (ja)	1991-07-15	1995-11-08	日本石油株式会社	ヒトリンパ球の癌細胞に対する傷害活性を高める方法
JPH06172203A (ja)	1992-12-02	1994-06-21	Takara Shuzo Co Ltd	フィブロネクチンレセプター産生異常細胞抑制剤
JPH06306096A (ja) *	1993-02-26	1994-11-01	Fuji Photo Film Co Ltd	ペプチド誘導体及びその用途
GB9315810D0 (en)	1993-07-30	1993-09-15	Univ London	Stabilised materials
DE4336399A1 (de)	1993-10-26	1995-04-27	Augustinus Dr Med Bader	Verfahren zur Verbesserung der Matrixbedingungen bipolar adhärierter Hepatozyten und zur Herstellung eines entsprechend konfigurierten Zellkulturkits
US6821778B1 (en) *	1993-12-01	2004-11-23	The Board Of Trustees Of Leland Stanford Junior University	Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
DE4412794A1 (de) *	1994-04-14	1995-12-14	Univ Ludwigs Albert	Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
GB9413029D0 (en)	1994-06-29	1994-08-17	Common Services Agency	Stem cell immobilisation
US5827642A (en)	1994-08-31	1998-10-27	Fred Hutchinson Cancer Research Center	Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5824547A (en)	1994-11-29	1998-10-20	Takara Shuzo Co., Ltd.	Method for production of transfected cells
JPH11506902A (ja)	1994-12-01	1999-06-22	ベスイズレイルディーコネスメディカルセンターインコーポレイテッド	イン・ビトロｔリンパ球生成系
US7067318B2 (en) *	1995-06-07	2006-06-27	The Regents Of The University Of Michigan	Methods for transfecting T cells
ATE292689T1 (de) *	1995-05-04	2005-04-15	Us Navy	Verbesserte verfahren zur transfektion der t- zellen
US6692964B1 (en) *	1995-05-04	2004-02-17	The United States Of America As Represented By The Secretary Of The Navy	Methods for transfecting T cells
JP3391941B2 (ja)	1995-06-15	2003-03-31	アサヒビール株式会社	余剰汚泥の処理方法
WO1997001194A1 (de)	1995-06-21	1997-01-09	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Elektrochemisches festelektrolyt-zellsystem
JPH0925299A (ja)	1995-07-13	1997-01-28	Sumitomo Electric Ind Ltd	Ｃｄ４４リガンド
EP0852618A1 (en)	1995-07-25	1998-07-15	Celltherapy Inc.	Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
DE19537494C2 (de)	1995-09-25	1997-10-02	Desitin Arzneimittel Gmbh	Kreatin zum Schutz von neuralem Gewebe
WO1997011604A1 (en)	1995-09-29	1997-04-03	Indiana University Foundation	Methods for enhanced virus-mediated dna transfer using molecules with virus- and cell-binding domains
CN100390290C (zh) *	1995-11-13	2008-05-28	宝生物工程株式会社	用逆转录病毒将基因转入靶细胞的方法
US6734014B1 (en) *	1996-02-08	2004-05-11	The United States Of America As Represented By The Department Of Health And Human Services	Methods and compositions for transforming dendritic cells and activating T cells
EP0904350B1 (en) *	1996-03-04	2010-08-04	Calyx Bio-Ventures Inc.	Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
AU726198B2 (en)	1996-03-04	2000-11-02	Targeted Genetics Corporation	Modified rapid expansion methods ("modified-REM") for in vitro propagation of T lymphocytes
JPH1029952A (ja)	1996-07-16	1998-02-03	Takara Shuzo Co Ltd	ヒト免疫不全ウイルス感染の制御用組成物および制御方法
CA2267288A1 (en)	1996-09-23	1998-03-26	Ontogeny, Inc.	Hematopoietic stem cells and methods for generating such cells
AU6140998A (en)	1997-01-31	1998-08-25	Epimmune, Inc.	Peptides and peptide-loaded antigen presenting cells for the activation of ctl
JP3591286B2 (ja)	1997-04-24	2004-11-17	セイコーエプソン株式会社	タイミング調整方法、印字装置及び調整パターン作成方法
TWI239352B (en) *	1997-07-23	2005-09-11	Takara Bio Inc	Gene transfer method with the use of serum-free medium
EP1047708B1 (en)	1997-12-24	2007-09-26	Bracco International B.V.	Peptide chelators that predominately form a single stereoisomeric species upon coordination to a metal center
EP1992640A1 (en)	1997-12-24	2008-11-19	Corixa Corporation	Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
JP2002522513A (ja)	1998-08-11	2002-07-23	アメリカ合衆国	哺乳動物細胞を形質導入する方法およびそれに関連する産物
EP1163912B1 (en)	1999-03-23	2007-10-31	Takara Bio Inc.	Gene therapeutics
ATE373078T1 (de)	2000-02-24	2007-09-15	Xcyte Therapies Inc	Gleichzeitige stimulation und konzentration von zellen
US6797514B2 (en) *	2000-02-24	2004-09-28	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
JP3904374B2 (ja) *	2000-02-29	2007-04-11	独立行政法人科学技術振興機構	キラー活性を増強したリンパ球
AU2001278734A1 (en) *	2000-08-16	2002-02-25	Takara Bio Inc.	Method of extensive culture of antigen-specific cytotoxic t cells
KR20040048379A (ko) *	2001-06-01	2004-06-09	싸이트 테라피스 인코포레이티드	Ｔ 세포 유도된 조직 복구 및 재생
CN101633907B (zh) *	2001-08-15	2012-09-05	宝生物工程株式会社	抗原特异性细胞毒性t细胞的扩大培养方法
JP4759890B2 (ja)	2001-09-12	2011-08-31	大日本印刷株式会社	パール調印刷物の印刷濃度管理方法
US7745140B2 (en) *	2002-01-03	2010-06-29	The Trustees Of The University Of Pennsylvania	Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
ATE491021T1 (de)	2002-03-25	2010-12-15	Takara Bio Inc	Verfahren zur produktion eines zytotoxischen lymphozyten
WO2004018667A1 (ja)	2002-08-26	2004-03-04	Kirin Beer Kabushiki Kaisha	ペプチド及びこれを含む医薬
CN1839202B (zh)	2003-08-22	2012-07-18	宝生物工程株式会社	细胞毒性淋巴细胞的制备方法

2003
- 2003-03-25 AT AT03712887T patent/ATE491021T1/de not_active IP Right Cessation
- 2003-03-25 TW TW099128980A patent/TW201043699A/zh unknown
- 2003-03-25 WO PCT/JP2003/003575 patent/WO2003080817A1/ja active Application Filing
- 2003-03-25 EP EP03712887A patent/EP1496109B1/en not_active Expired - Lifetime
- 2003-03-25 KR KR1020047014928A patent/KR100786054B1/ko active IP Right Grant
- 2003-03-25 EP EP10184353A patent/EP2305796B1/en not_active Expired - Lifetime
- 2003-03-25 EP EP10185168A patent/EP2305793B1/en not_active Expired - Lifetime
- 2003-03-25 JP JP2003578546A patent/JP4406566B2/ja not_active Expired - Lifetime
- 2003-03-25 CN CN03811464A patent/CN100591760C/zh not_active Expired - Lifetime
- 2003-03-25 ES ES10185168T patent/ES2396447T3/es not_active Expired - Lifetime
- 2003-03-25 ES ES10184353T patent/ES2397319T3/es not_active Expired - Lifetime
- 2003-03-25 EA EA200401242A patent/EA010434B1/ru not_active IP Right Cessation
- 2003-03-25 MX MXPA04009287A patent/MXPA04009287A/es active IP Right Grant
- 2003-03-25 ES ES03712887T patent/ES2356814T3/es not_active Expired - Lifetime
- 2003-03-25 TW TW092106632A patent/TWI334442B/zh not_active IP Right Cessation
- 2003-03-25 CN CN2011102215061A patent/CN102321579A/zh active Pending
- 2003-03-25 KR KR1020067027270A patent/KR100895231B1/ko not_active IP Right Cessation
- 2003-03-25 CN CN2009102171437A patent/CN101735981B/zh not_active Expired - Fee Related
- 2003-03-25 DE DE60335253T patent/DE60335253D1/de not_active Expired - Lifetime
- 2003-03-25 AU AU2003221073A patent/AU2003221073B2/en not_active Ceased
- 2003-03-25 US US10/509,055 patent/US8728811B2/en active Active
- 2003-03-25 CA CA2479288A patent/CA2479288C/en not_active Expired - Lifetime
2005
- 2005-12-12 HK HK05111402.4A patent/HK1079543A1/xx not_active IP Right Cessation
2007
- 2007-07-31 US US11/831,423 patent/US20080227204A1/en not_active Abandoned
2008
- 2008-11-12 AU AU2008243221A patent/AU2008243221B2/en not_active Ceased
2010
- 2010-11-15 HK HK10110610.7A patent/HK1144105A1/xx not_active IP Right Cessation
2014
- 2014-04-10 US US14/250,227 patent/US8975070B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US8728811B2 (en)	2014-05-20
US20050227354A1 (en)	2005-10-13
EP1496109A1 (en)	2005-01-12
EP1496109B1 (en)	2010-12-08
ES2396447T3 (es)	2013-02-21
ES2397319T3 (es)	2013-03-06
KR20070015620A (ko)	2007-02-05
ATE491021T1 (de)	2010-12-15
CN100591760C (zh)	2010-02-24
TW201043699A (en)	2010-12-16
JPWO2003080817A1 (ja)	2005-07-28
EP2305796A1 (en)	2011-04-06
US20080227204A1 (en)	2008-09-18
EP2305793B1 (en)	2012-10-17
WO2003080817A1 (en)	2003-10-02
US8975070B2 (en)	2015-03-10
CA2479288A1 (en)	2003-10-02
AU2008243221B2 (en)	2011-10-27
KR20040099352A (ko)	2004-11-26
TWI334442B (en)	2010-12-11
DE60335253D1 (de)	2011-01-20
EP2305793A1 (en)	2011-04-06
AU2003221073A1 (en)	2003-10-08
EA200401242A1 (ru)	2005-04-28
AU2008243221A1 (en)	2008-12-04
CN1656215A (zh)	2005-08-17
CA2479288C (en)	2015-02-24
KR100786054B1 (ko)	2007-12-17
AU2003221073B2 (en)	2008-08-21
CN102321579A (zh)	2012-01-18
MXPA04009287A (es)	2005-01-25
TW200400265A (en)	2004-01-01
CN101735981A (zh)	2010-06-16
KR100895231B1 (ko)	2009-05-04
JP4406566B2 (ja)	2010-01-27
CN101735981B (zh)	2013-01-02
EP1496109A4 (en)	2006-07-19
ES2356814T3 (es)	2011-04-13
US20140212972A1 (en)	2014-07-31
EP2305796B1 (en)	2012-10-24
HK1144105A1 (en)	2011-01-28
EA010434B1 (ru)	2008-08-29

Legal Events

Date	Code	Title	Description
2023-04-06	PE	Patent expired	Effective date: 20230327

Publication	Publication Date	Title
HK1144105A1 (en)	2011-01-28	Process for producing cytotoxic lymphocyte
HK1095606A1 (en)	2007-05-11	Process for producing cytotoxic lymphocytes
EP1484292A4 (en)	2009-01-28	GLASS COMPOSITION FOR THE MANUFACTURE OF INORGANIC FIBER, MANUFACTURING METHOD AND PRODUCT MADE OF THE INORGANIC FIBER
IL140419A0 (en)	2002-02-10	Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
ZA200203994B (en)	2003-01-02	Method of fuel production from Fischer-Tropsch process.
MXPA03010322A (es)	2004-02-17	PROCEDIMIENTO PARA LA PREPARACIoN DE POLIISOCIANATOS.
ATE304614T1 (de)	2005-09-15	Verfahren zur herstellung metallisches molybdäns
IL151678A (en)	2005-08-31	Method for producing asymmetrical 4,6-bis (aryloxy) pyrimidine derivatives
EP1408099A4 (en)	2004-10-06	TECHNIQUE FOR PRODUCING HYDROCARBON ACCORDING TO THE FISCHER-TROPSCH PROCESS
IL164625A0 (en)	2005-12-18	Method for producing monoclonal antibodies
AU2002313208A1 (en)	2003-05-15	Method for producing hydrocarbons by fischer-tropsch process
MXPA03009806A (es)	2004-01-29	Derivados de piperazino y su uso como inhibidor de fosfodiesterasa de nucleotido ciclico de tipo 4 (pde4).
IL152295A0 (en)	2003-05-29	Method for producing 2-alkyl-3-chlorophenols
HUP0300902A3 (en)	2005-02-28	Method for producing bicyclic 1,3-diketones
IL143079A0 (en)	2002-04-21	Process for the production of cyclene
MXPA03010670A (es)	2004-03-02	Metodo para producir almidon o productos con almidon a partir de mateias primas vegetales con almidon.
IL133923A0 (en)	2001-04-30	Method for preparing 3-cyano-2,4-dihalogen-5-fluoro-benzoic acid
AU2002226308A1 (en)	2002-04-08	Method for producing dnda
IL166374A0 (en)	2006-01-16	Novel process for producing imidazoÄ1,2-bÜpyridazine derivative
AU2003238198A8 (en)	2003-12-31	Method for producing 4,6-dichloro-5-fluoropyrimidine
AU2002358557A1 (en)	2003-09-22	Improved method for the production of biphosphites
GB9805808D0 (en)	1998-05-13	Process for producing meat products
MXPA05010990A (es)	2005-12-12	Procedimiento de preparacion del 4, 10beta-diacetoxi-2alfa-benzoiloxi-5beta, 20-epoxi-1,13alfa-dihidroxi-9-oxo-19-norciclopropa[g] tax-11-eno
IL146257A0 (en)	2002-07-25	Method of producing methoxyimido acetic amide
IL161800A0 (en)	2005-11-20	Method for the production of desclarithromycin, and intermediateproducts